124 related articles for article (PubMed ID: 21830929)
1. BayesWeb: a user-friendly platform for exploratory Bayesian analysis of safety signals from small clinical trials.
Scott JA; Hand AL; Sian LS
J Biopharm Stat; 2011 Sep; 21(5):1030-41. PubMed ID: 21830929
[TBL] [Abstract][Full Text] [Related]
2. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
Xia HA; Ma H; Carlin BP
J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
[TBL] [Abstract][Full Text] [Related]
3. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
4. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
Wang M; Day R
J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
[TBL] [Abstract][Full Text] [Related]
5. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
6. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
7. Bayesian population approaches to the analysis of dose escalation studies.
Russu A; De Nicolao G; Poggesi I; Neve M; Gomeni R
Comput Methods Programs Biomed; 2012 Aug; 107(2):189-201. PubMed ID: 21764475
[TBL] [Abstract][Full Text] [Related]
8. Dose-finding in phase I clinical trials based on toxicity probability intervals.
Ji Y; Li Y; Nebiyou Bekele B
Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
[TBL] [Abstract][Full Text] [Related]
9. np1: a computer program for dose escalation strategies in phase I clinical trials.
Kramar A; Houédé N; Paoletti X
Comput Methods Programs Biomed; 2007 Oct; 88(1):8-17. PubMed ID: 17719124
[TBL] [Abstract][Full Text] [Related]
10. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
Zohar S; Chevret S
J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
[TBL] [Abstract][Full Text] [Related]
11. Practical Bayesian design and analysis for drug and device clinical trials.
Hobbs BP; Carlin BP
J Biopharm Stat; 2008; 18(1):54-80. PubMed ID: 18161542
[TBL] [Abstract][Full Text] [Related]
12. Bayesian adaptive clinical trials: a dream for statisticians only?
Chevret S
Stat Med; 2012 May; 31(11-12):1002-13. PubMed ID: 21905067
[TBL] [Abstract][Full Text] [Related]
13. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
14. Implementing a decision-theoretic design in clinical trials: why and how?
Palmer CR; Shahumyan H
Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
[TBL] [Abstract][Full Text] [Related]
15. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.
Thall PF; Russell KE
Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520
[TBL] [Abstract][Full Text] [Related]
16. Adaptive designs for Phase I dose-finding studies.
Zhou Y
Fundam Clin Pharmacol; 2010 Apr; 24(2):129-38. PubMed ID: 19703268
[TBL] [Abstract][Full Text] [Related]
17. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Thall PF; Cook JD; Estey EH
J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
[TBL] [Abstract][Full Text] [Related]
18. The i3+3 design for phase I clinical trials.
Liu M; Wang SJ; Ji Y
J Biopharm Stat; 2020 Mar; 30(2):294-304. PubMed ID: 31304864
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian dose finding design for dual endpoint phase I trials.
Loke YC; Tan SB; Cai Y; Machin D
Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
[TBL] [Abstract][Full Text] [Related]
20. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]